Acorda Therapeutics
ACOR
ACOR was delisted on the 11th of April, 2024.
178 hedge funds and large institutions have $1.01B invested in Acorda Therapeutics in 2017 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 67 increasing their positions, 59 reducing their positions, and 19 closing their positions.
42% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 19
14% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 59
12% more capital invested
Capital invested by funds: $899M → $1.01B (+$111M)
2% more funds holding
Funds holding: 175 → 178 (+3)
75% less call options, than puts
Call options by funds: $24.3M | Put options by funds: $96.7M
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$154M |
| 2 |
SCM
Scopia Capital Management
New York
|
+$24.9M |
| 3 |
CI
Cambiar Investors
Denver,
Colorado
|
+$20M |
| 4 |
CCM
Consonance Capital Management
New York
|
+$14.9M |
| 5 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$12.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$17.6M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$15M |
| 3 |
PA
Perceptive Advisors
New York
|
-$13.5M |
| 4 |
BC
Broadfin Capital
New York
|
-$12.1M |
| 5 |
AC
Armistice Capital
New York
|
-$8.05M |
ACOR Hedge Fund Activity: Q1 2017 in Review
178 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q1 2017, worth a combined $1.01B — up 12% from $899M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new ACOR positions and 19 closed out — a net gain of 8 holders — while 67 added to existing stakes and 59 trimmed.
The largest buyer was BlackRock, adding an estimated $154M. The largest seller was Eagle Asset Management, exiting entirely with an estimated $17.6M sold.
- 178 institutional investors held Acorda Therapeutics (ACOR) as of Q1 2017, up from 175 in Q4 2016.
- Funds reported $1.01B of Acorda Therapeutics stock for Q1 2017, up 12% quarter-over-quarter.
- 27 funds opened new Acorda Therapeutics positions in Q1 2017 and 19 closed out, a net change of +8 holders.
- The largest Acorda Therapeutics buyer in Q1 2017 was BlackRock, an estimated $154M added.
- The largest Acorda Therapeutics seller in Q1 2017 was Eagle Asset Management, an estimated $17.6M sold.
Based on aggregated 13F filings for Q1 2017.